(주)에이프로젠바이오로직스 · KOSPI: 003060 · Pharmaceuticals and medicinal chemicals
| KRW | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | ₩87.4B | ₩67.4B | ₩73.2B |
| Operating income | −₩57.5B | −₩52.8B | −₩60.4B |
| Net income | −₩115.3B | −₩105.0B | −₩168.3B |
| Total assets | ₩589.4B | ₩591.0B | ₩587.0B |
| Total liabilities | ₩220.7B | ₩212.3B | ₩309.4B |
| Total equity | ₩368.7B | ₩378.7B | ₩277.6B |
| Share capital | ₩332.9B | ₩99.2B | ₩99.2B |
Consolidated statements · FY2025 operating margin -82.4% · liabilities to equity 111% · Annual report FY2025 (Korean original)
| Period | Auditor | Opinion |
|---|---|---|
| Term 67 (current) | 대성회계법인 (구, 대성삼경회계법인) | Unqualified |
| Term 66 (prior) | 대성삼경회계법인 | Unqualified |
| Term 65 (two years prior) | 대주회계법인 | Unqualified |
| Date | Largest shareholder (Korean) | Stake | Cause (Korean) |
|---|---|---|---|
| 2023년 01월 02일 | ㈜에이프로젠 | — | 장외매도 |
| 2024년 06월 28일 | ㈜에이프로젠 | — | 유상증자 참여 |
| 2024년 08월 02일 | ㈜에이프로젠 | — | 유상증자 참여 |
| 2024년 08월 13일 | ㈜에이프로젠 | — | 유상증자 참여 |
| 2024년 08월 20일 | ㈜에이프로젠 | — | 장외매도 |
| 2023년 01월 12일 | ㈜에이프로젠 | — | 장외매도 |
| 2023년 01월 25일 | ㈜에이프로젠 | — | 장외매도 |
| 2023년 02월 06일 | ㈜에이프로젠 | — | 장외매도 |
| 2023년 04월 13일 | ㈜에이프로젠 | — | 유상증자 참여 |
| 2023년 09월 06일 | ㈜에이프로젠 | — | 장외매도 |
| Date | Filing | Original |
|---|---|---|
| 2026-09-11 | Amended: Material event report — Paid-in capital increase (rights offering) decision | DART |
| 2026-09-11 | Large shareholding (5%+) report | DART |
| 2026-09-03 | Material event report — Paid-in capital increase (rights offering) decision | DART |
| 2026-09-02 | Officer / major shareholder ownership report | DART |
| 2026-09-02 | Large shareholding (5%+) report | DART |
| 2026-09-02 | Large shareholding (5%+) report | DART |
| 2026-08-21 | Large shareholding (5%+) report | DART |
| 2026-08-13 | Half-year report (2026.06) | DART |
| 2026-08-11 | Large shareholding (5%+) report | DART |
| 2026-08-07 | Large shareholding (5%+) report | DART |
| 2026-07-31 | Change in shareholdings of largest shareholder | DART |
| 2026-07-31 | Officer / major shareholder ownership report | DART |
| 2026-07-31 | Large shareholding (5%+) report | DART |
| 2026-07-28 | Adjustment of conversion / exercise / exchange price (notice) | DART |
| 2026-07-27 | Results of share or equity-linked bond issuance (voluntary) | DART |
| 2026-07-23 | Large shareholding (5%+) report | DART |
| 2026-07-14 | Material event report — Paid-in capital increase (rights offering) decision | DART |
| 2026-07-07 | Large shareholding (5%+) report | DART |
| 2026-07-01 | Results of share or equity-linked bond issuance (voluntary) | DART |
| 2026-06-29 | Amended: Material event report — Convertible bond issuance decision | DART |
Showing the 20 most recent of 73 filings. The full brief lists all of them.
For business customers. EU companies: enter your VAT number at checkout and no VAT is charged (reverse charge).
Data generated 2026-09-16 from OpenDART.
This page summarizes public filings from DART, the official electronic disclosure system of Korea. It is not investment, credit or legal advice. Figures are shown in the currency the company reports in. Titles and labels are machine-translated and may contain errors — always check the linked original filing. Source: OpenDART, Financial Supervisory Service, Korea.